Hyperfine Announces Alzheimer's Research with Promising Swoop® System Data and Advanced Image Quality
Today's presentation at CTAD, a leading international Alzheimer's conference, expands research supporting the value of ultra-low-field MRI in monitoring amyloid-related imaging abnormalities (ARIA).
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the presentation of additional research data and images using the Swoop® system to image patients with Alzheimer's disease who are part of the observational, investigator-initiated CARE PMR study.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more